As the acute phase of the COVID-19 pandemic recedes, a growing number of individuals experiencing long COVID are reporting new or worsened respiratory issues, including allergies, and asthma. This suggests the virus’s impact extends far beyond initial infection, potentially triggering lasting immunological changes. The rise in these conditions is prompting medical professionals to re-evaluate the long-term consequences of COVID-19 and to encourage those with new or escalating symptoms to seek medical attention.
The connection between COVID-19 and the development of new allergies and asthma is complex, but researchers are increasingly focusing on the role of prolonged inflammation and a condition known as mast cell activation syndrome (MCAS). At least 65 million people worldwide are currently living with long COVID-19, with the majority falling within the 36-50 age range, according to research published in the Asia Pacific Allergy journal. This demographic is often at the peak of their productive years, making the impact of long-term health issues particularly significant.
Understanding Mast Cell Activation Syndrome
Mast cell activation syndrome, or MCAS, involves a malfunction of mast cells – immune cells that release inflammatory mediators like histamine. In individuals with MCAS, these cells inappropriately release excessive amounts of these substances, leading to a wide range of symptoms that can mimic allergic reactions. A study by Weinstock et al., highlighted in recent research, indicates that patients with long COVID-19 exhibit a clinical syndrome remarkably similar to that seen in patients diagnosed with MCAS. This suggests that COVID-19 may trigger or exacerbate mast cell activation, contributing to the development of allergy-like symptoms and respiratory problems.
The research, published in Immunological dysfunction and mast cell activation syndrome in long COVID, details how the activation of mast cells in long COVID-19 is characterized by abnormal granulation and excessive release of inflammatory cytokines. These cytokines contribute to systemic inflammation, which can affect multiple organ systems and contribute to the diverse symptoms experienced by long COVID patients.
Long COVID: Beyond Fatigue and Brain Fog
For much of the pandemic, long COVID was primarily associated with symptoms like fatigue and “brain fog.” However, the emerging evidence suggests a broader spectrum of long-term health issues, including a significant increase in respiratory and allergy-related conditions. This shift in understanding underscores the demand for a more comprehensive approach to diagnosing and managing long COVID.
Sayeef Hossain Khan, assistant professor and medicine specialist at Popular Diagnostic Centre in Dhaka, Bangladesh, emphasizes that long COVID is no longer limited to its initial, well-known symptoms. He advises that anyone experiencing new breathing problems, allergies, or asthma symptoms after recovering from COVID-19 should promptly seek medical attention.
What Should Patients Do?
If you are experiencing new or worsening allergy or asthma symptoms after a COVID-19 infection, it’s crucial to consult with a healthcare professional. Diagnosis and treatment of MCAS, when present, can provide symptomatic relief and assist manage the hyperinflammation states often seen in long COVID patients. Early intervention can potentially improve long-term control and recovery.
Currently, there isn’t a single, standardized treatment for MCAS associated with long COVID. Management typically involves a combination of strategies aimed at reducing mast cell activation and controlling symptoms. These may include antihistamines, mast cell stabilizers, and dietary modifications. Further research is needed to determine the most effective treatment approaches.
The Ongoing Impact of the Pandemic
The increasing recognition of long COVID’s impact on allergies and asthma serves as a reminder that the effects of the pandemic are far from over. Even as the acute phase subsides, the long-term health consequences continue to unfold, requiring ongoing research and vigilance. The overlap between long COVID and other postviral infection syndromes also suggests that advances in understanding these conditions could benefit a wider range of patients.
The World Health Organization (WHO) has acknowledged that a notable portion of individuals affected by long COVID develop new allergies or experience a worsening of existing ones, though specific prevalence rates are still being studied. The organization continues to monitor the evolving landscape of long COVID and its associated health challenges.
The next major update on long COVID research and treatment guidelines is expected from the National Institutes of Health (NIH) in late 2026, following the completion of several ongoing clinical trials. Staying informed about these developments is crucial for both patients and healthcare providers.
Have you experienced new or worsening allergies or asthma after a COVID-19 infection? Share your story in the comments below, and please share this article with anyone who might find it helpful.
